Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) and Rosy Wellness have announced the launch of a consumer awareness campaign for DARE to PLAY™ Sildenafil Cream, a groundbreaking topical formulation for women's arousal targeted for prescription availability in Q4 2025.
The campaign leverages Rosy's platform of 250,000+ women and includes an Arousal Collection and educational "Quickie" videos featuring expert Dr. Sameena Rahman. The product contains sildenafil (Viagra's active ingredient) and is clinically proven to improve genital blood flow and sexual response. This collaboration marks the first phase of a broader initiative that will include healthcare provider awareness and customer support programs.
DARE to PLAY™ will be available as a compounded drug under Section 503B of the FDCA, representing a significant advancement in women's sexual health treatment backed by clinical evidence.
Daré Bioscience (NASDAQ: DARE) announced a live webinar scheduled for August 6, 2025, to showcase DARE to PLAY™, their innovative sildenafil cream for female sexual arousal. The product, containing the same active ingredient as Viagra®, is the first and only evidence-backed sildenafil cream formulation for women, designed to improve genital blood flow and sexual response.
The webinar will feature prominent sexual health experts, including Dr. Irwin Goldstein, discussing clinical evidence and the product's proprietary formulation. DARE to PLAY™ is expected to be available by prescription in Q4 2025. The event, hosted in collaboration with The National Association of Nurse Practitioners in Women's Health, is open to clinicians, investors, and women interested in science-based sexual health solutions.
Daré Bioscience (NASDAQ: DARE) announced positive interim Phase 3 results for Ovaprene®, their investigational hormone-free monthly intravaginal contraceptive. The Data Safety Monitoring Board recommended continuing the study without modifications after reviewing safety data.
Key interim findings show a 9% pregnancy rate among treated women, aligning with pre-pivotal study expectations. While 17% of participants discontinued due to vaginal odor, no serious safety concerns were identified. The ongoing multicenter study targets 250 participants for 12-month use evaluation.
Bayer holds rights to obtain exclusive U.S. commercialization through a $20 million payment post-trial completion, with potential earnings of up to $310 million in commercial milestones plus double-digit tiered royalties.
Daré Bioscience (NASDAQ: DARE) has received a $6 million non-dilutive grant installment for developing DARE-LARC1, bringing the total received to $37.8 million of a $49 million commitment. DARE-LARC1 is a preclinical-stage long-acting reversible contraceptive utilizing their intelligent drug delivery system (DARE-IDDS) platform.
The DARE-IDDS platform, originally developed at MIT, features wireless control, precision dosing, and extended duration capabilities. The technology can deliver hundreds of individualized doses over months or years without recharging. Beyond contraception, the platform shows potential applications in obesity, diabetes, and other chronic conditions requiring precise, long-term dosing.
The company is actively exploring strategic partnerships to expand the platform's use beyond reproductive health, with $11.2 million in additional non-dilutive funding available upon achieving specific milestones.
Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has scheduled its Q1 2025 financial results and company update conference call for May 13, 2025, at 4:30 p.m. Eastern Time. Investors can access the call via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 3461324. A live webcast will be available on the company's investor relations website, with replay access until May 27, 2025.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will deliver a keynote address at the Fierce Pharma Engage summit on April 29, 2025. The presentation, titled 'Breaking Barriers, Building Access: Communicating Bold Moves in Women's Health Innovation,' will focus on the company's expanded business strategy incorporating 503B compounding.
The company recently unveiled a dual-path approach for its proprietary Sildenafil Cream formulation, targeting prescription availability in Q4 2025. Daré's portfolio includes XACIATO™, an FDA-approved bacterial vaginosis treatment licensed to Organon, and several first-in-category candidates:
- Ovaprene® - hormone-free monthly contraceptive (licensed to Bayer)
- Sildenafil Cream, 3.6% - for female sexual arousal disorder
- DARE-HRT1 - bio-identical hormone therapy ring
Daré Bioscience (NASDAQ: DARE) has announced its expanded business strategy featuring a dual-path approach for its proprietary Sildenafil Cream formulation, with plans to make it available via prescription in Q4 2025. The company's President and CEO, Sabrina Martucci Johnson, will present these developments at the Jones Healthcare and Technology Innovation Conference on April 9th, 2025.
The strategy includes utilizing Section 503B compounding to expedite market access for select Daré proprietary formulations. The company is also exploring bringing consumer health products to market without prescription requirements. Additional strategic partnerships and timing updates are expected this quarter.
The presentation will be accessible via webcast at 1:00 p.m. PT, with a replay available until April 23, 2025, through the company's investor relations website.